Abstract 1258: Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor
Brandhuber, Barbara, Ku, Karin, Lallena, Maria J., Baquero, Carmen, Choy, Regina, Ebata, Kevin, Lin, Sophie Shu, Jiang, Lihua, Liu, Yanxin, Chen, Xiangling, Lou, Liguang
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Abstract 2531: FCN-683, a novel second-generation BCL-2 inhibitor, is highly potent, selective and efficacious against clinically relevant venetoclax-resistant mutations
Lin, Shu (Sophie), Liu, Hongbin, Tan, Rui, Zhang, Weipeng, He, Chengxi, Rong, Yue, Huang, Zhuo, Yu, Jinhua, Wang, Yunling, Qi, Yangli, Zhao, Xingdong, Jiang, Lihua, Liu, Yanxin, Wang, Xilei, Zou, Zongyao, Sun, Jing, Gao, Yuwei, Wang, Weibo, Guan, Xiaohui, Wu, Yifang
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article